Re: The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis

Similar Items

• Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
  by: Carolina L. Haass‐Koffler
  Published: (2026)
• Comment on Domzaridou et al .: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment
  by: Adam Bakker, et al.
  Published: (2024)
• Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
  by: Nadine Ezard, et al.
  Published: (2025)
• The glucagon‐like peptide‐1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery
  by: Mariel Molina‐Castro, et al.
  Published: (2024)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  by: Filip K. Knop, et al.
  Published: (2024)